Eden Research plc Voting Rights, Warrants and Options Outstanding (9018Y)

TIDMEDEN

RNS Number : 9018Y

Eden Research plc

08 March 2017

8 March 2017

Eden Research Plc

("Eden" or "Company")

Total Voting Rights and Warrants and Options Outstanding

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural bio-control products and microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, is today confirming its current total voting rights and number of options and warrants outstanding:

The Company's total issued and voting share capital comprises 184,654,119 ordinary shares of 1 pence each ("Ordinary Shares"). No shares were held in treasury at the date of this announcement. The total number of current voting rights in the Company is therefore 184,654,119.

The above figure (184,654,119 Ordinary Shares) is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company.

The Company also confirms that the current number of outstanding warrants over Ordinary Shares ("Warrants") is currently 5,497,867, which is unchanged from the number of Warrants in issue announced by the Company on 27 September 2016. This number includes 2,000,000 Warrants with an exercise price of 11 pence which were issued to Oxford Capital Limited. These Warrants were issued in December 2014 in connection with the 20,865,382 new Ordinary Shares issued, as announced by the Company on 28 November 2014, for settlement of all outstanding debt.

In addition, the Company confirms that the current number of outstanding options over Ordinary Shares is currently 5,025,000.

 
Eden Research plc                                 www.edenresearch.com 
Sean Smith, Chief Executive                         Tel: [phone] 
 Officer 
Alex Abrey, Chief Financial 
 Officer 
 
Shore Capital and Corporate                           www.shorecap.com 
 Limited 
Stephane Auton/Patrick                              Tel: [phone] 
 Castle 
 
Walbrook PR Ltd              Tel: [phone] or [e-mail] 
Paul McManus                                        Mob: [phone] 
Lianne Cawthorne                                    Mob: [phone] 
 

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of GBP12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represents a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy and France.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFVSVTITIID

(END) Dow Jones Newswires

March 08, 2017 09:40 ET (14:40 GMT)